Patient Enrollment Completed in Ph 3 Trial Evaluating a Domvanalimab-Containing Regimen in 1L Metastatic Upper GI Cancers June 18, 2024
Ph 1 Trial of Menin Inhibitor HMPL-506 Initiated in Patients with Hematological Malignancies in China June 11, 2024
Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial June 4, 2024
First Patient Enrolled in AFFIRM-205, a Ph III Study of LAE002 (afuresertib) + Fulvestrant for Treatment of Breast Cancer June 3, 2024
First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC June 3, 2024
First Patient Dosed in Global Tumor-Agnostic Ph 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors June 3, 2024
First Patient Dosed in Randomized Ph 2 Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy May 29, 2024
First Patient Dosed in Investigator-Initiated Trial (IIT) of Danvatirsen in Ph 1 for AML/MDS Cancers May 21, 2024
